GB201607393D0 - Biomarkers for early diagnosis of ovarian cancer - Google Patents
Biomarkers for early diagnosis of ovarian cancerInfo
- Publication number
- GB201607393D0 GB201607393D0 GBGB1607393.4A GB201607393A GB201607393D0 GB 201607393 D0 GB201607393 D0 GB 201607393D0 GB 201607393 A GB201607393 A GB 201607393A GB 201607393 D0 GB201607393 D0 GB 201607393D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- biomarkers
- ovarian cancer
- early diagnosis
- diagnosis
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 238000013399 early diagnosis Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1607393.4A GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1607393.4A GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201607393D0 true GB201607393D0 (en) | 2016-06-15 |
| GB2549763A GB2549763A (en) | 2017-11-01 |
Family
ID=56234031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1607393.4A Withdrawn GB2549763A (en) | 2016-04-28 | 2016-04-28 | Biomarkers for early diagnosis of ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2549763A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111735950A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit |
| CN111735949A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of Wnt7a and CA125 as early ovarian cancer biomarker and kit |
| CN111912987A (en) * | 2020-08-25 | 2020-11-10 | 北京信诺卫康科技有限公司 | Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit |
| CN114015689A (en) * | 2021-10-26 | 2022-02-08 | 江苏大学 | A shRNA sequence that specifically inhibits GOS2 gene expression and its application |
| CN116716404A (en) * | 2023-06-13 | 2023-09-08 | 中国医学科学院北京协和医院 | Device to distinguish ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
| CN116790759A (en) * | 2023-08-08 | 2023-09-22 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
| CN117936076A (en) * | 2024-01-31 | 2024-04-26 | 中国医学科学院北京协和医院 | Construction method and application of keratoconus diagnostic model |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020101432A1 (en) * | 2018-11-16 | 2020-05-22 | 가톨릭대학교 산학협력단 | Biomarker for predicting onset of hereditary ovarian cancer and use thereof |
| KR102368717B1 (en) * | 2018-11-16 | 2022-02-28 | 가톨릭대학교 산학협력단 | Biomarker for predicting development of hereditary ovarian cancer and use thereof |
| CN112951325B (en) * | 2021-02-18 | 2023-04-21 | 北京吉因加医学检验实验室有限公司 | Design method of probe combination for cancer detection and application thereof |
-
2016
- 2016-04-28 GB GB1607393.4A patent/GB2549763A/en not_active Withdrawn
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111735949A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of Wnt7a and CA125 as early ovarian cancer biomarker and kit |
| CN111735950B (en) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Combination of FGF18 and CA125 as biomarker and kit for early ovarian cancer |
| CN111735950A (en) * | 2020-07-17 | 2020-10-02 | 北京信诺卫康科技有限公司 | Combination of FGF18 and CA125 as early ovarian cancer biomarker and kit |
| CN111912987A (en) * | 2020-08-25 | 2020-11-10 | 北京信诺卫康科技有限公司 | Combination of FGF18 and HE4 as early ovarian cancer biomarker and kit |
| CN111912987B (en) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Combination of FGF18 and HE4 as biomarker and kit for early ovarian cancer |
| CN114015689B (en) * | 2021-10-26 | 2024-06-07 | 江苏大学 | ShRNA sequence for specifically inhibiting GOS2 gene expression and application thereof |
| CN114015689A (en) * | 2021-10-26 | 2022-02-08 | 江苏大学 | A shRNA sequence that specifically inhibits GOS2 gene expression and its application |
| CN116716404A (en) * | 2023-06-13 | 2023-09-08 | 中国医学科学院北京协和医院 | Device to distinguish ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
| CN116716404B (en) * | 2023-06-13 | 2024-01-30 | 中国医学科学院北京协和医院 | Device to distinguish ovarian clear cell carcinoma from high-grade serous carcinoma based on S100A2 |
| CN116790759B (en) * | 2023-08-08 | 2023-12-01 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
| CN116790759A (en) * | 2023-08-08 | 2023-09-22 | 潍坊医学院 | Application of PLEC in early diagnosis and treatment of epithelial ovarian cancer |
| CN117936076A (en) * | 2024-01-31 | 2024-04-26 | 中国医学科学院北京协和医院 | Construction method and application of keratoconus diagnostic model |
| CN117936076B (en) * | 2024-01-31 | 2024-11-12 | 中国医学科学院北京协和医院 | Construction method and application of keratoconus diagnostic model |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2549763A (en) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201607393D0 (en) | Biomarkers for early diagnosis of ovarian cancer | |
| ZA201701753B (en) | Biomarkers for assessing breast cancer | |
| IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
| IL253756B (en) | Biomarker panel for the detection of cancer | |
| SG10202011339RA (en) | Microrna biomarker for the diagnosis of gastric cancer | |
| PL3474736T3 (en) | Olfactory detector for early diagnosis of ovarian cancer | |
| EP3140426A4 (en) | Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma | |
| SG11201706223VA (en) | Biomarkers for pancreatic cancer | |
| SG10202110526WA (en) | Biomarkers for cancer therapeutics | |
| IL251376A0 (en) | Methods for assessing risk of developing breast cancer | |
| SG11201606106SA (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| PL3593139T3 (en) | Cancer biomarkers | |
| GB201500584D0 (en) | Cancer biomarkers | |
| IL266199A (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| EP3204008A4 (en) | Use of biomarkers for predicting clinical sensitivity to cancer treatment | |
| SG10201913528PA (en) | Methods of diagnosing cancer | |
| GB201719639D0 (en) | Setection of biomarkers | |
| SG11201701875YA (en) | Methods for detecting ovarian cancer | |
| DK3198034T3 (en) | BIOMARKERS FOR CERVIX CANCERS | |
| SG11201701076TA (en) | Diagnosis of cancer | |
| GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
| GB201517028D0 (en) | Novel biomarkers for pancreatic cancer | |
| EP3278111A4 (en) | Biomarkers for detection of ovarian cancer | |
| EP3189332A4 (en) | Biomarkers for detection of breast cancer | |
| GB201617722D0 (en) | Method for determining prognosis of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |